Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) Profit After Tax (2020 - 2026)

Edgewise Therapeutics has reported Profit After Tax over the past 7 years, most recently at -$49.0 million for Q1 2026.

  • Quarterly results put Profit After Tax at -$49.0 million for Q1 2026, down 20.14% from a year ago — trailing twelve months through Mar 2026 was -$176.0 million (down 20.48% YoY), and the annual figure for FY2025 was -$167.8 million, down 25.4%.
  • Profit After Tax reached -$49.0 million in Q1 2026 per EWTX's latest filing, up from -$50.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$14.7 million in Q1 2022 and bottomed at -$50.2 million in Q4 2025.
  • Median Profit After Tax over the past 5 years was -$30.1 million (2023), compared with a mean of -$30.5 million.
  • The largest annual shift saw Profit After Tax tumbled 115.11% in 2022 before it dropped 14.66% in 2025.
  • Over 5 years, Profit After Tax stood at -$19.4 million in 2022, then tumbled by 55.26% to -$30.1 million in 2023, then plummeted by 31.58% to -$39.7 million in 2024, then decreased by 26.61% to -$50.2 million in 2025, then grew by 2.4% to -$49.0 million in 2026.
  • Business Quant data shows Profit After Tax for EWTX at -$49.0 million in Q1 2026, -$50.2 million in Q4 2025, and -$40.7 million in Q3 2025.